⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →

Aurobindo Pharma Limited (AUROPHARMA) — Announcement | 13 August 2026(2 announcements)

· NSE 🔴 High Importance Neutral
By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings
1 Announcement 🔴 High Importance Neutral 📄 PDF
📢 Key Event
Aurobindo Pharma incorporates wholly owned subsidiary Auropharm Overseas Limited
💡 Investor Takeaway
The new subsidiary enables global expansion plans without immediate capital outlay or regulatory hurdles.

Aurobindo Pharma announced the incorporation of a new wholly owned subsidiary, Auropharm Overseas Limited, incorporated on August 13, 2026, to undertake manufacturing and marketing operations in India and foreign countries. The subsidiary was created with an initial paid-up capital of Rs. 10 lakh through 100,000 equity shares of Rs. 10 each, fully subscribed in cash. This move establishes a dedicated entity for international expansion without requiring regulatory approvals or external acquisition costs.

2 Announcement Neutral 📄 PDF
📢 Key Event
Aurobindo Pharma reports 16% YoY revenue growth to Rs. 9,150 crores in Q1 FY27 with strong international performance and biosimilar progress
🔄 What Changed
Revenue growth accelerated to 16% YoY from previous quarters, gross margin held at 60.4%, and EBITDA margin improved to 21% compared to prior periods
🔮 What's Next
FY27 guidance includes double-digit growth in Europe (20%+ EBITDA), single-digit growth for Eugia (~500M revenue), and positive EBITDA for China after prior 7M loss
💡 Investor Takeaway
Shareholders should note accelerating growth in international markets and biosimilars, with strategic expansion reducing reliance on domestic formulation growth

Aurobindo Pharma reported 16% YoY revenue growth to Rs. 9,150 crores in Q1 FY27, driven by strong formulation and international markets, with EBITDA at Rs. 1,924 crores (21% margin) and gross margin of 60.4%. The company completed the Lannett acquisition, expanded capacity in China and Europe, and advanced biosimilar pipelines including US FDA filings for Omalizumab and Denosumab. Management highlighted strategic focus on high-return businesses and expects double-digit growth in Europe and positive EBITDA from China operations.

⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →
📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Limited (AUROPHARMA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹96,836.1 Cr P/E: 26.3 ROE: 9.8% ROCE: 12.8% Div Yield: 0.24%

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 13 August 2026

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day

⚡ StockFin Pro Go Pro — bigger Radar, no daily limits Upgrade

© 2026 StockFin.ai — AI-powered Indian stock research

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd